1-20 of 28
Aditya Bardia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-1073
Published: 19 August 2024
View article titled, Elacestrant in ER<sup>+</sup>, HER2<sup>−</sup> Metastatic Breast Cancer with <em>ESR1</em>-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Open the PDF for Elacestrant in ER<sup>+</sup>, HER2<sup>−</sup> Metastatic Breast Cancer with <em>ESR1</em>-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T. Coates, Bogang Wu, Rachel O. Abelman, Laura Spring, Beverly Moy, Phoebe Ryan, Mark N. Melkonyan, Ann Partridge, Dejan Juric, Jeffrey Peppercorn, Heather Parsons, Seth A. Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven J. Isakoff, Sara M. Tolaney, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2917–2924.
https://doi.org/10.1158/1078-0432.CCR-24-0428
Published: 15 July 2024
View article titled, Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Open the PDF for Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cracking the Genomic Code of CDK4/6 Inhibitor Resistance

Seth A. Wander, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2008–2010.
https://doi.org/10.1158/1078-0432.CCR-23-3413
Published: 15 May 2024
View article titled, Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
Open the PDF for Cracking the Genomic Code of CDK4/6 Inhibitor Resistance in another window
Journal Articles

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Komal L. Jhaveri, Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni, Joohyuk Sohn, Tomas G. Neilan, Rafael Villanueva-Vázquez, Peter Kabos, Laura García-Estévez, Elena López-Miranda, J. Alejandro Pérez-Fidalgo, Jose M. Pérez-García, Jiajie Yu, Jill Fredrickson, Heather M. Moore, Ching-Wei Chang, John W. Bond, Jennifer Eng-Wong, Mary R. Gates, Elgene Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 754–766.
https://doi.org/10.1158/1078-0432.CCR-23-1796
Published: 16 February 2024
View article titled, Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Open the PDF for Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception

Arielle J. Medford, Beverly Moy, Laura M. Spring, Sara A. Hurvitz, Nicholas C. Turner, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4540–4548.
https://doi.org/10.1158/1078-0432.CCR-23-0757
Published: 14 November 2023
View article titled, Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception
Open the PDF for Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception in another window
Journal Articles

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Whitney L. Hensing, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli, Andrew A. Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3092–3100.
https://doi.org/10.1158/1078-0432.CCR-22-3785
Published: 15 August 2023
View article titled, Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Open the PDF for Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

Sarat Chandarlapaty, Maura N. Dickler, Jose Alejandro Perez Fidalgo, Rafael Villanueva-Vázquez, Jennifer Giltnane, Mary Gates, Ching-Wei Chang, Sravanthi Cheeti, Jill Fredrickson, Xiaojing Wang, Ann Collier, Heather M. Moore, Ciara Metcalfe, Jennifer Lauchle, Eric W. Humke, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2781–2790.
https://doi.org/10.1158/1078-0432.CCR-23-0011
Published: 01 August 2023
View article titled, An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Open the PDF for An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen, Katarzyna J. Jerzak, Xinni Song, Thomas Decker, Frances Boyle, Steve McCune, Anne Armstrong, Catherine Shannon, Gianfilippo Bertelli, Ching-Wei Chang, Rupal Desai, Kushagra Gupta, Timothy R. Wilson, Aulde Flechais, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3256–3267.
https://doi.org/10.1158/1078-0432.CCR-21-3811
Published: 02 August 2022
View article titled, VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Open the PDF for VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results in another window
Includes: Supplementary data
Journal Articles

Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities

Maxwell R. Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 821–830.
https://doi.org/10.1158/1078-0432.CCR-21-2947
Published: 01 March 2022
View article titled, Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
Open the PDF for Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities in another window
Journal Articles

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 851–859.
https://doi.org/10.1158/1078-0432.CCR-21-3032
Published: 01 March 2022
View article titled, Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Open the PDF for Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Aditya Bardia, Sara A. Hurvitz, Angela DeMichele, Amy S. Clark, Amelia Zelnak, Denise A. Yardley, Meghan Karuturi, Tara Sanft, Sibel Blau, Lowell Hart, Cynthia Ma, Hope S. Rugo, Das Purkayastha, Stacy Moulder
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (15): 4177–4185.
https://doi.org/10.1158/1078-0432.CCR-20-2114
Published: 01 August 2021
View article titled, Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Open the PDF for Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) in another window
Includes: Supplementary data
Journal Articles

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

Neelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, Megan Yuen, Jochen Lennerz, A. John Iafrate, Seth A. Wander, Laura Spring, Dejan Juric, Steven Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3404–3413.
https://doi.org/10.1158/1078-0432.CCR-20-3444
Published: 15 June 2021
View article titled, Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Open the PDF for Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer

Saya Jacob, Andrew A. Davis, Lorenzo Gerratana, Marko Velimirovic, Ami N. Shah, Firas Wehbe, Neelima Katam, Qiang Zhang, Lisa Flaum, Kalliopi P. Siziopikou, Leonidas C. Platanias, William J. Gradishar, Amir Behdad, Aditya Bardia, Massimo Cristofanilli
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1361–1370.
https://doi.org/10.1158/1078-0432.CCR-20-1566
Published: 01 March 2021
View article titled, The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
Open the PDF for The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer

Aditya Bardia, Shanu Modi, Mafalda Oliveira, Javier Cortes, Mario Campone, Brigette Ma, Luc Dirix, Amy Weise, Becker Hewes, Ivan Diaz-Padilla, Yu Han, Priya Deshpande, Tanay S. Samant, Karen Rodriguez Lorenc, Wei He, Fei Su, Mariana Chavez-MacGregor
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6417–6428.
https://doi.org/10.1158/1078-0432.CCR-20-1068
Published: 15 December 2020
View article titled, Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer
Open the PDF for Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

Neelima Vidula, Taronish Dubash, Michael S. Lawrence, Antoine Simoneau, Andrzej Niemierko, Erica Blouch, Becky Nagy, Whijae Roh, Brian Chirn, Brittany A. Reeves, Giuliana Malvarosa, Jochen Lennerz, Steven J. Isakoff, Dejan Juric, Douglas Micalizzi, Seth Wander, Laura Spring, Beverly Moy, Kristen Shannon, Jerry Younger, Richard Lanman, Mehmet Toner, A. John Iafrate, Gad Getz, Lee Zou, Leif W. Ellisen, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4852–4862.
https://doi.org/10.1158/1078-0432.CCR-20-0638
Published: 15 September 2020
View article titled, Identification of Somatically Acquired <em>BRCA1/2</em> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Open the PDF for Identification of Somatically Acquired <em>BRCA1/2</em> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Laura M. Spring, Geoffrey Fell, Andrea Arfe, Chandni Sharma, Rachel Greenup, Kerry L. Reynolds, Barbara L. Smith, Brian Alexander, Beverly Moy, Steven J. Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2838–2848.
https://doi.org/10.1158/1078-0432.CCR-19-3492
Published: 15 June 2020
View article titled, Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Open the PDF for Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis in another window
Includes: Supplementary data
Journal Articles

Abstract IA18: Molecular signatures of circulating tumor cells

Daniel Haber, Xin Hong, Richard Ebright, Doug Micalizi, Aditya Bardia, Ryan Sullivan, Mehmet Toner, Shyamala Maheswaran
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): IA18.
https://doi.org/10.1158/1557-3265.LiqBiop20-IA18
Published: 01 June 2020
View article titled, Abstract IA18: Molecular signatures of circulating tumor cells
Journal Articles

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors

Neelima Vidula, Thereasa A. Rich, Oliver Sartor, Jennifer Yen, Aaron Hardin, Tracy Nance, Michael B. Lilly, Mohammad Amin Nezami, Sandip P. Patel, Benedito A. Carneiro, Alice C. Fan, Adam M. Brufsky, Barbara A. Parker, Benjamin B. Bridges, Neeraj Agarwal, Benjamin L. Maughan, Victoria M. Raymond, Stephen R. Fairclough, Richard B. Lanman, Aditya Bardia, Massimo Cristofanilli
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2546–2555.
https://doi.org/10.1158/1078-0432.CCR-19-2933
Published: 01 June 2020
View article titled, Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <em>BRCA</em> Mutations among Patients with Advanced Solid Tumors
Open the PDF for Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <em>BRCA</em> Mutations among Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6443–6451.
https://doi.org/10.1158/1078-0432.CCR-19-0138
Published: 01 November 2019
View article titled, <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer
Open the PDF for <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials

Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, José Baselga, Henry C. Manning, Umar Mahmood, Gary A. Ulaner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1435.
https://doi.org/10.1158/1078-0432.CCR-18-4266
Published: 15 February 2019
View article titled, Correction: <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Open the PDF for Correction: <sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials in another window